IOVA - Iovance Biotherapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
22.80
+0.58 (+2.61%)
At close: 4:00PM EST

22.58 -0.22 (-0.96%)
After hours: 4:11PM EST

Stock chart is not supported by your current browser
Previous Close22.22
Open22.18
Bid22.82 x 900
Ask22.80 x 3000
Day's Range22.17 - 22.95
52 Week Range7.26 - 26.59
Volume1,063,463
Avg. Volume1,278,043
Market Cap2.877B
Beta (3Y Monthly)1.97
PE Ratio (TTM)N/A
EPS (TTM)-1.36
Earnings DateNov 4, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est35.25
  • ETF Trends

    The Unloved Biotechnology ETF Rally

    Biotechnology stocks have been outperforming over the past month, but ETF investors seem disinterested and are even trimming exposure to this sector. In a weekly update on the flow of money in and out of stock funds, PiperJaffray analyst Christopher J. Raymond pointed out that investors pulled a net $99 million out of healthcare and biotech-related funds in the one-week period ended on Wednesday, Barron's reports. The latest redemptions seems surprising given the recent outperformance of the biotechnology sector.

  • GlobeNewswire

    Iovance Biotherapeutics Announces Updated Phase 2 Clinical Data from the Lifileucel Metastatic Melanoma Trial at the Society for Immunotherapy of Cancer 34th Annual Meeting

    Iovance Biotherapeutics, Inc. (IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that new data from Cohort 2 of the ongoing Phase 2 lifileucel metastatic melanoma study (C-144-01) were presented Friday, Nov. 8, 2019, at the Society for Immunotherapy of Cancer (SITC) 34th Annual Meeting in National Harbor, Maryland (Abstract P865). Median DOR was not reached as assessed by either IRC (range: 1.6+ to 21.2+ months) or investigator (range: 2.2 to 21.2+ months) at 11.3 months median follow up. In addition, based on the most recent data cut from the study, median DOR was not reached as assessed by investigator at 12.8 months of median study follow-up.

  • GlobeNewswire

    Iovance Biotherapeutics to Present at Upcoming Investor Conferences in November

    Iovance Biotherapeutics intends to improve patient care by making T cell-based immunotherapies broadly accessible for the treatment of patients with solid tumors and blood cancers. Tumor infiltrating lymphocyte (TIL) therapy uses a patient’s own immune cells to attack cancer.

  • GlobeNewswire

    Iovance Biotherapeutics Reports Third Quarter and September Year-to-Date 2019 Financial Results

    - Late-breaking abstract at Society for Immunotherapy of Cancer (SITC) meeting to feature Independent Review Committee (IRC) read results from Cohort 2 of C-144-01.

  • GlobeNewswire

    Iovance Biotherapeutics to Host Third Quarter 2019 Financial Results Conference Call and Webcast on Monday, November 4, 2019

    Iovance Biotherapeutics, Inc. (IOVA), a late-stage biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that it will report its third quarter 2019 financial results on Monday, November 4, 2019. The live webcast can be accessed under “News & Events” in the Investors section of the Company’s website at www.iovance.com or at the link: https://edge.media-server.com/mmc/p/9ohu47kv. Iovance Biotherapeutics intends to improve patient care by making T cell-based immunotherapies broadly accessible for the treatment of patients with solid tumors and blood cancers.

  • Hedge Funds Are Dumping Iovance Biotherapeutics, Inc. (IOVA)
    Insider Monkey

    Hedge Funds Are Dumping Iovance Biotherapeutics, Inc. (IOVA)

    Hedge funds are known to underperform the bull markets but that's not because they are bad at investing. Truth be told, most hedge fund managers and other smaller players within this industry are very smart and skilled investors. Of course, they may also make wrong bets in some instances, but no one knows what the […]

  • GlobeNewswire

    Iovance Biotherapeutics Announces Four Abstracts to be Presented at the Upcoming 2019 SITC Annual Meeting

    Iovance Biotherapeutics, Inc. (IOVA), a late-stage biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that four abstracts highlighting its TIL therapy will be presented at the upcoming Society for Immunotherapy of Cancer (SITC) 34th Annual Meeting from November 6-10, 2019 in National Harbor, Maryland. Tumor infiltrating lymphocyte (TIL) therapy uses a patient’s own immune cells to attack cancer.

  • Benzinga

    Stifel Bullish On Iovance And Fate Therapeutics, Neutral On Bluebird Bio

    Stifel initiated coverage on a trio of oncology-focused biotechs Tuesday, recommending buying two and staying sidelined on a third. The Analyst Benjamin Burnett initiated coverage of: bluebird bio Inc ...

  • GlobeNewswire

    Iovance Biotherapeutics to Present at Upcoming Conferences

    Live and archived webcasts of the Cell & Gene Meeting on the Mesa and 2019 Cantor Global Healthcare Conference presentations will be available in the Investors section of the Iovance website at http://ir.iovance.com. Iovance Biotherapeutics intends to improve patient care by making T cell-based immunotherapies broadly accessible for the treatment of patients with solid tumors and blood cancers. Tumor infiltrating lymphocyte (TIL) therapy uses a patient’s own immune cells to attack cancer.

  • Have Insiders Been Buying Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Shares This Year?
    Simply Wall St.

    Have Insiders Been Buying Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Shares This Year?

    We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. The...

  • Iovance Biotherapeutics: Technical Analysis and Strategy
    TheStreet.com

    Iovance Biotherapeutics: Technical Analysis and Strategy

    Iovance Biotherapeutics is worth speculating on, as the company's cancer treatments are promising, Jim Cramer said during his Mad Money program Friday night. IOVA intends to commercialize "autologous cell therapy products for solid tumors and blood cancers." Their approach uses a patient's own immune cells to attack cancer cells -- cutting edge stuff, if you ask me. In the daily bar chart of IOVA, below, we can see that prices made a seven-plus month base around $10 before a gap to the upside got the rally going.

  • Iovance Biotherapeutics: Buy the Dip?
    Motley Fool

    Iovance Biotherapeutics: Buy the Dip?

    The company is flush with cash and wields a promising therapeutic pipeline. Is its recent tumble a buying opportunity?

  • GlobeNewswire

    Iovance Biotherapeutics to Present at Upcoming Investor Conferences in September

    Live and archived webcasts of the presentations will be available by visiting the Investors section of the Iovance Biotherapeutics website at http://ir.iovance.com. Iovance Biotherapeutics intends to commercialize autologous cell therapy products for solid tumors and blood cancers. Tumor infiltrating lymphocyte (TIL) therapy uses a patient’s own immune cells to attack cancer cells.

  • IOVA Stock Could See Another Massive Rebound
    Schaeffer's Investment Research

    IOVA Stock Could See Another Massive Rebound

    A bullish signal just flashed for IOVA that could have it trading back near its five-year highs

  • Iovance Biotherapeutics, Inc. (IOVA) Q2 2019 Earnings Call Transcript
    Motley Fool

    Iovance Biotherapeutics, Inc. (IOVA) Q2 2019 Earnings Call Transcript

    IOVA earnings call for the period ending June 30, 2019.

  • Biotech Merger Activity Has Been Hot In 2019 — So, What's One More?
    Investor's Business Daily

    Biotech Merger Activity Has Been Hot In 2019 — So, What's One More?

    Iovance Biotherapeutics hit a "clear inflection point" in the second quarter, analysts said Friday — but that didn't stop the biotech stock from plunging on wider-than-expected losses.

  • GlobeNewswire

    Iovance Biotherapeutics Reports Second Quarter 2019 Financial Results and Provides Corporate Update

    - Regulatory submission for LN-145 in advanced cervical cancer expected in the second half of 2020 -- Company to host conference call at 4:30 p.m. EDT today - SAN CARLOS,.

  • 3 Top Biotech Stocks to Buy Right Now
    Motley Fool

    3 Top Biotech Stocks to Buy Right Now

    These three biotech stocks might be outstanding buys right now.

  • GlobeNewswire

    Iovance Biotherapeutics to Host Second Quarter 2019 Financial Results Conference Call and Webcast on Thursday, August 1, 2019

    Iovance Biotherapeutics, Inc. (IOVA), a late-stage biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that it will report its second quarter 2019 financial results on Thursday, August 1, 2019. Iovance Biotherapeutics intends to commercialize autologous cell therapy products for solid tumors and blood cancers.  Tumor infiltrating lymphocyte (TIL) therapy uses a patient’s own cancer-fighting immune cells to attack solid tumors. TIL are extracted from tumor cells, and once expanded through a proprietary process are infused back into the patient.

  • GlobeNewswire

    Iovance Biotherapeutics Appoints Friedrich Graf Finckenstein, M.D., as Chief Medical Officer

    Iovance Biotherapeutics, Inc. (IOVA), a late-stage biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced the appointment of Friedrich Graf Finckenstein, M.D., as chief medical officer. Dr. Graf Finckenstein brings over 19 years of experience in clinical development and translational research to the company. “We are very pleased to have Dr. Finckenstein join Iovance as we move forward with pivotal studies for lifileucel in metastatic melanoma and LN-145 in metastatic cervical cancer,” said Maria Fardis, Ph.D., president and chief executive officer of Iovance Biotherapeutics.

  • Does Market Volatility Impact Iovance Biotherapeutics, Inc.'s (NASDAQ:IOVA) Share Price?
    Simply Wall St.

    Does Market Volatility Impact Iovance Biotherapeutics, Inc.'s (NASDAQ:IOVA) Share Price?

    If you own shares in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) then it's worth thinking about how it contributes to...

  • Here's Why Iovance Biotherapeutics Soared 50% in June
    Motley Fool

    Here's Why Iovance Biotherapeutics Soared 50% in June

    The clinical-stage biopharma announced promising data at a major conference.

  • GlobeNewswire

    Iovance Biotherapeutics Provides Cervical Cancer Program Updates Following End of Phase 2 Meeting with U.S. Food and Drug Administration (FDA)

    Iovance Biotherapeutics, Inc. (IOVA), a late-stage biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today provided an update on the regulatory path for LN-145 in advanced cervical cancer. Based on an End of Phase 2 meeting held with the U.S. Food and Drug Administration (FDA), the FDA has acknowledged that the ongoing innovaTIL-04 study of TIL therapy LN-145 may be sufficient to support registration in the treatment of patients with advanced cervical cancer. The study is being enrolled with a prospective definition of objective response rate (ORR) read out by a Blinded Independent Review Committee (BIRC) as the primary endpoint.  In accordance with the FDA’s recommendation, the new version of the protocol will further define the patient population.

  • 3 Stocks With a Perfect Smart Score
    TipRanks

    3 Stocks With a Perfect Smart Score

    The S&P 500 recently closed out an all-time high of 2,954, while the Dow is also within touching distance of record territory. That’s excellent news for existing shareholders, but it does make finding new investing ideas a challenge. However, a deep analysis of stocks – covering everything from analyst activity to headline sentiment and even momentum – can turn up a few stock picks that are still primed to outperform. The Smart Score pulls together eight data sets – including the factors mentioned above – to create a rating that unites eight different equity insights.Here are three “Perfect 10” stocks to buy now, according to the Smart Score system. All three stocks boast the highest possible score of “10,” indicating that these stocks represent compelling investing opportunities right now. Let’s see why these stocks earn such high scores… Iovance (IOVA)Iovance Biotherapeutics is a clinical-stage biotech focused on developing immunotherapies to treat cancer. Specifically, the company is working on personalized tumor infiltrating lymphocytes known as TILs. What’s exciting is that Iovance's proprietary TILs are the first cell therapy to show significant efficacy in solid tumors. Right now the company is conducting phase II clinical trials assessing the efficacy and safety of TILs for patients with metastatic melanoma, head and neck cancer, as well as cervical cancer. Shares have more than doubled year-to-date, and as we can see below the stock scores a ‘perfect’ Smart Score of 10. Most notably, 9 analysts have published buy ratings on the stock in the last three months. So no hold or sell ratings here. Analysts reiterated their bullish calls after IOVA presented two posters at the annual meeting of the American Society of Clinical Oncology (ASCO), showing encouraging efficacy of TILs in melanoma and cervival cancer. “Iovance’s TIL products, LN-144 and LN-145, are continuing to deliver significant clinical promise in these two indications, and we believe investors are starting to recognize and reward it” wrote Chardan Capital’s Geulah Livshits following the event. Her buy rating comes with a $30 price target (41% upside potential). But that’s not the only datapoint in IOVA’s favor. The stock also boasts bullish blogger opinions, increased hedge fund activity and a very positive sentiment from investors. Five-star blogger Bhavneesh Sharma rates IOVA a buy. He explains that Iovance is being rumored as an attractive takeover candidate after breakthrough results of its TILs technology in advanced refractory cervical cancer. Netflix (NFLX)Streaming giant Netflix looks like a compelling investing proposition right now, according to its Smart Score. Indeed, top-rated Goldman Sachs analyst Heath Terry has placed Netflix on the firm’s elite Conviction List of top stock ideas. He wasn’t deterred by the company’s light second-quarter guidance, writing: “As Netflix’s content investments, distribution partnerships and marketing spend drive subscriber growth significantly above consensus expectations and the company approaches an inflection point in cash profitability, we believe shares of NFLX will continue to significantly outperform,” he said.“We remain Buy rated and raise our 12-month price target to $460 from $450 to reflect faster subscriber growth expectations, particularly in international markets.” From current levels that indicates upside potential of 24%.Terry is one of 24 analysts who have recently published NFLX buy ratings. That’s versus just 3 hold ratings and 1 sell rating. Encouragingly, Piper Jaffray’s Michael Olson has also just carried out a deep dive into Netflix’s second quarter. He revealed that his study of search trends suggests year-over-year 11.7% growth in US subscribers and 45.8% international growth. That easily beats Netflix’s guidance of 8.2%. for US subscribers, and international growth of 36.5%.Meanwhile, the company also enjoys Very Bullish news sentiment, blogger opinions, increased hedge fund activity and positive return on equity. News sentiment is buzzing as Netflix has just revealed that its new comedy caper “Murder Mystery” enjoyed the biggest opening weekend ever for a Netflix Film. According to the firm’s tweet, “30,869,863 accounts watched ‘Murder Mystery’ in its first 3 days.” Paycom Software (PAYC)Based in Oklahoma, Paycom is an online payroll and human resource technology provider. It is attributed with being one of the first fully online payroll providers and has offices throughout the US. Shares have exploded 84% year-to-date, thanks to strong earnings results and a guidance raise. The company reported revenue growth of 30% and adjusted EBITDA of $103 million. According to five-star KeyBanc analyst Brent Bracelin further growth lies ahead. He has just boosted his price target from $215 to $246. “Further analysis of the HR competitive landscape suggests the growth and improving margin profile at HR SaaS leader PAYC appears sustainable, particularly given roughly 70% of HR applications are still tied to on-premise deployments implying a long and stable growth runway” comments Bracelin. He raises estimates citing increased confidence in the company maintaining industry leading growth rate while improving margins.In addition, investors show Very Positive sentiment on PAYC, as do hedge funds and bloggers. Hedge fund gurus with promininent positions in the stock include both Ken Fisher and Joel Greenblatt of Gotham Asset Management. Discover more Top Smart Score stocks here